Production (Stage)
Channel Therapeutics Corporation
CHRO
$1.22
-$0.0065-0.53%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 18.00% | -7.78% | -118.91% | -162.31% | -188.19% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -76.30% | 267.69% | 72.16% | 474.54% | 409.77% |
| Total Other Non-Cash Items | -61.03% | -65.48% | 292.06% | 401.03% | 993.62% |
| Change in Net Operating Assets | -9.42% | -98.31% | -103.67% | -147.02% | 3.38% |
| Cash from Operations | -58.34% | -490.47% | -324.47% | -330.41% | -101.52% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 31.03% | -30.08% | 25.02% | 105.51% | -39.52% |
| Total Debt Repaid | 100.00% | -- | -- | -- | -- |
| Issuance of Common Stock | -98.67% | 2,270.63% | 1,374.99% | 1,374.99% | 1,357.38% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -- | -- | -- | -- |
| Cash from Financing | -87.83% | 507.40% | 488.49% | 474.91% | 353.55% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -197.78% | 909.69% | 918.67% | 2,822.26% | 7,557.61% |